

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE.....	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION.....	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References	31
GENERAL REMARKS.....	33
MALARIA	41
1. Exposure Data	41
1.1 Taxonomy, structure, and biology of <i>Plasmodium</i>	41
1.2 Epidemiology of <i>Plasmodium</i> infection.....	45
2. Cancer in Humans.....	53
2.1 Burkitt lymphoma	54
2.2 Kaposi sarcoma	72
2.3 Cancers at other sites	74
2.4 Susceptible populations.....	75
3. Cancer in Experimental Animals	75
3.1 Mouse.....	75
3.2 Rat	77

4. Mechanistic and Other Relevant Data.....	77
4.1 Malaria and the host immune system	77
4.2 Biological properties of <i>P. falciparum</i> antigens relevant to immune dysfunction.....	87
4.3 Other infectious agents associated with falciparum malaria and human cancer.....	91
4.4 <i>Plasmodium</i> infection in experimental animals	97
4.5 Susceptible populations.....	97
4.6 Mechanisms of lymphomagenesis	97
5. Summary of Data Reported.....	99
5.1 Exposure Data.....	99
5.2 Human carcinogenicity data	99
5.3 Animal carcinogenicity data	100
5.4 Mechanistic and other relevant data.....	100
6. Evaluation and Rationale.....	101
6.1 Cancer in humans	101
6.2 Cancer in experimental animals	101
6.3 Mechanistic and other relevant data.....	101
6.4 Overall evaluation	101
References	101

INTRODUCTION TO POLYOMAVIRUSES.....	121
1. Discovery	121
2. Taxonomy and phylogeny	123
3. Structure of the virion	123
4. Genomic organization, gene products, and replication	124
5. Viral life-cycle	127
6. Host range.....	128
References	128

SIMIAN VIRUS 40.....	133
1. Exposure Data	133
1.1 Host range and tissue tropism.....	133
1.2 Methods for the detection of SV40 infection	133
1.3 Epidemiology of infection.....	134
2. Cancer in Humans.....	142
2.1 Prospective studies.....	142
2.2 Case-control studies	153
2.3 Susceptible populations.....	162
2.4 Case series	167
3. Cancer in Experimental Animals	169
3.1 Infection with SV40.....	169
3.2 Infection with SV40 DNA	182
3.3 Transgenic mouse models.....	182
3.4 Carcinogenicity of SV40 in combination with asbestos	190

4. Mechanistic and Other Relevant Data	190
4.1 Transforming capacity of SV40	190
4.2 Biological properties and regulation of SV40 viral proteins relevant to carcinogenesis	191
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role for SV40 in human malignancies	194
4.4 Interaction between SV40 and potential cofactors	198
4.5 Transgenic models for cancers associated with SV40 infection	198
4.6 Susceptible human populations	198
4.7 Mechanistic considerations in relation to carcinogenesis	199
5. Summary of Data Reported	201
5.1 Exposure data	201
5.2 Human carcinogenicity data	201
5.3 Animal carcinogenicity data	202
5.4 Mechanistic and other relevant data	203
6. Evaluation	203
6.1 Cancer in humans	203
6.2 Cancer in experimental animals	203
6.3 Overall evaluation	203
6.4 Rationale	203
References	204
BK POLYOMAVIRUS	215
1. Exposure Data	215
1.1 Cell and tissue tropism	215
1.2 Methods for the detection of BKV	215
1.3 Epidemiology of BKV infection	217
2. Cancer in Humans	221
2.1 Background	222
2.2 Cancer of the prostate	223
2.3 Cancer of the colon	227
2.4 Haematological malignancies	228
2.5 Neuroblastoma	229
2.6 Cancer of the brain	229
2.7 Cancer of the head and neck	229
2.8 Cancer of the bladder	230
2.9 Cancer of the ovary	230
2.10 Precursors to cancer of the cervix	230
2.11 Cancers of the renal pelvis and kidneys	230
2.12 Cancer risk among patients with polyomavirus-associated nephropathy (PVAN)	231
3. Cancer in Experimental Animals	231
3.1 Hamster	231
3.2 Mouse	240
3.3 Rat	240
3.4 Hamsters injected with BKV DNA	241
3.5 Hamsters injected with BKV and c-Ha- <i>ras</i> DNA	241
3.6 Transgenic mouse models of BKV T-antigen with natural viral promoter	241

4. Mechanistic and Other Relevant Data.....	241
4.1 Transforming capacity of BKV.....	241
4.2 Relevant biological properties of BKV viral proteins.....	243
4.3 Association of BKV with human tumours.....	243
4.4 Transgenic models for cancers associated with BKV infection	246
4.5 Susceptible human populations.....	246
4.6 Mechanistic considerations	247
5. Summary of Data Reported.....	249
5.1 Exposure data	249
5.2 Human carcinogenicity data	249
5.3 Animal carcinogenicity data	250
5.4 Mechanistic and other relevant data.....	250
6. Evaluation	251
6.1 Cancer in humans	251
6.2 Cancer in experimental animals	251
6.3 Overall evaluation	251
References	251

JC POLYOMAVIRUS	261
1. Exposure Data	261
1.1 Cell and tissue tropism.....	261
1.2 Methods for the detection of JCV	261
1.3 Epidemiology of JCV infection.....	262
2. Cancer in Humans.....	265
2.1 Background.....	266
2.2 Cancer of the colorectum.....	266
2.3 Non-Hodgkin lymphoma (NHL)	272
2.4 Cancer of the brain	273
2.5 Cancer of the bladder	274
2.6 Childhood malignancies.....	274
2.7 Other cancers	276
2.8 Intervention studies.....	277
2.9 Susceptible populations.....	281
3. Cancer in Experimental Animals	281
3.1 Monkey	281
3.2 Hamster	281
3.3 Rat	286
3.4 Transgenic mouse models	287
4. Mechanistic and Other Relevant Data.....	289
4.1 Transforming capacity of JCV	289
4.2 Relevant biological properties of JCV viral proteins	289
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role of JCV in human malignancies.....	290
4.4 Transgenic models for cancers associated with JCV infection.....	296
4.5 Susceptible human populations.....	296
4.6 Mechanistic considerations	296

5. Summary of Data Reported.....	298
5.1 Exposure data	298
5.2 Human carcinogenicity data	298
5.3 Animal carcinogenicity data	299
5.4 Mechanistic and other relevant data.....	299
6. Evaluation	300
6.1 Cancer in humans	300
6.2 Cancer in experimental animals	300
6.3 Overall evaluation	300
References	300
MERKEL CELL POLYOMAVIRUS	309
1. Exposure Data	309
1.1 Cell and tissue tropism.....	309
1.2 Methods for the detection of MCV	309
1.3 Epidemiology of infection.....	311
1.4 Diseases associated with MCV	314
2. Cancer in Humans.....	314
2.1 Background.....	314
2.2 Case-control studies.....	314
2.3 Case series	318
2.4 Susceptible populations.....	327
3. Cancer in Experimental Animals	327
4. Mechanistic and Other Relevant Data.....	327
4.1 Transforming capacity of MCV.....	327
4.2 Relevant biological properties of MCV-encoded viral proteins	327
4.3 <i>In vivo</i> and <i>in vitro</i> evidence for a role of MCV in human malignancies	329
4.4 Interaction between MCV and other potential cofactors	339
4.5 Susceptible populations	339
4.6 Transgenic models for cancers associated with MCV infection.....	340
4.7 Mechanisms of carcinogenesis	340
5. Summary of Data Reported.....	343
5.1 Exposure data	343
5.2 Human carcinogenicity data	343
5.3 Animal carcinogenicity data	343
5.4 Mechanistic and other relevant data.....	343
6. Evaluation	344
6.1 Cancer in humans	344
6.2 Cancer in experimental animals	344
6.3 Overall evaluation	344
References	344
LIST OF ABBREVIATIONS	351